id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
ecj-9795	Aschieri, Daniela; Stabile, Marco; Maestri, Cristina; Rosato, Luca; Coccia, Michela Giovanna; Novara, Paola; Lanati, Gianluca; Di Dio, Maria Teresa; Franco, Cosimo; Bisceglie, Giuseppina; Leddi, Giuseppe; Fabrizi, Enrico; Rucci, Paola; Taliani, Gloria	Potential benefits of anticoagulant doses of low molecular weight heparin in COVID-19: An observational retrospective study	2021	6	.pdf	application/pdf	4440	206	46	The first case in Italy was reported on February 21, 2020 and, a few days later, Castel San Giovanni Hospital was entirely dedicated to the treatment of COVID-19 patients. Giuseppina Bisceglie,6 Giuseppe Leddi,5 Enrico Fabrizi,7 Paola Rucci,8 Gloria Taliani9 1Cardiology Unit, Emergency Department, Castel San Giovanni Hospital, ASL of Piacenza, Castel San Giovanni; 2Plastic Surgery Unit, Surgery Department, Castel San Giovanni Hospital, ASL of Piacenza, Castel San Giovanni; 3Emergency Care Unit, Castel San Giovanni Hospital, ASL of Piacenza, Castel San Giovanni; 4Respiratory Intensive Care Unit, Castel San Giovanni Hospital, ASL of Piacenza, Castel San Giovanni; 5Orthopedic Unit, Castel San Giovanni Hospital, ASL of Piacenza, Castel San Giovanni; 6General Medicine Unit, Castel San Giovanni Hospital, ASL of Piacenza, Castel San Giovanni; 7DISES and DSS, Università Cattolica del S. Cuore, Piacenza; 8Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum University, Bologna; 9Department of Translational and Precision Medicine, Sapienza University, Rome, Italy Non -co mmerc ial us e o nly systemic inflammation that induces diffuse endothelial injury and hypercoagulability state.2-5 The relationship between viral infec- tions and thrombosis is recognized, but it seems to be predominant in SARS-CoV2 infection, leading to life-threatening thrombotic complications such as venous and arterial thrombosis, pulmonary embolism and microvascular thrombi.6-8 Low Molecular Weight Heparin (LMWH) is recommended in COVID-19 patients by some expert consensus, but its efficacy and safety at therapeutic doses has not been described yet.9-11 We assumed that LMWH at therapeutic doses could exert a beneficial effect on the clinical course of COVID-19 thanks to its anticoagulant, anti-inflammatory and in vitro antiviral proper- ties.12-16 The aim of this observational study was to estimate the effect of anticoagulation on the in-hospital mortality of COVID-19.	cache/ecj-9795.pdf	txt/ecj-9795.txt